These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 6533925)

  • 21. Changes of metal concentrations in blood and peritoneal dialysate during long-term desferrioxamine B therapy.
    Romero RA; Salgado O; Elejalde LE; Rodríguez-Iturbe B; Tahán JE
    Transplant Proc; 1996 Dec; 28(6):3385-7. PubMed ID: 8962321
    [No Abstract]   [Full Text] [Related]  

  • 22. [Serum aluminum concentration and the deferoxamine test in a group of patients under chronic hemodialysis].
    de Sousa FT; Barbas JM; dos Santos JP; Mil-Homens MC; Aniceto JP; Melo JA; Rosário EM; Fonseca AP; Vizela MH
    Acta Med Port; 1986; 7(4):161-4. PubMed ID: 3825604
    [No Abstract]   [Full Text] [Related]  

  • 23. Desferrioxamine in the treatment of aluminum overload.
    Ackrill P; Day JP
    Clin Nephrol; 1985; 24 Suppl 1():S94-7. PubMed ID: 3842106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exacerbation of aluminium encephalopathy after treatment with desferrioxamine.
    Lillevang ST; Pedersen FB
    Nephrol Dial Transplant; 1989; 4(7):676. PubMed ID: 2510071
    [No Abstract]   [Full Text] [Related]  

  • 25. Desferrioxamine treatment for aluminium and iron overload in uraemic patients by haemodialysis or haemofiltration.
    Baldamus CA; Schmidt H; Scheuermann EH; Werner E; Kaltwasser JP; Schoeppe W
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():382-6. PubMed ID: 3991527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aluminum and iron overload in chronic dialysis.
    Ackrill P; Day JP; Ahmed R
    Kidney Int Suppl; 1988 Mar; 24():S163-7. PubMed ID: 3283407
    [No Abstract]   [Full Text] [Related]  

  • 27. [Desferal treatment of aluminum poisoning; effect on serum concentrations of aluminum (Al), iron (Fe) and copper (Cu)].
    Günther K; Winnefeld K; Stein G; Sperschneider H; Schröter H; Fünfstück R
    Z Urol Nephrol; 1986 Oct; 79(10):569-76. PubMed ID: 3811645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Speech apraxia in dialysis-associated aluminum encephalopathy].
    Haug BA; Botsch G; Felgenhauer K
    Nervenarzt; 1991 Oct; 62(10):637-40. PubMed ID: 1749454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concomitant removal of aluminium and iron by haemodialysis and haemofiltration after desferrioxamine intravenous infusion.
    Ciancioni C; Poignet JL; Naret C; Delons S; Mauras Y; Allain P; Man NK
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():469-73. PubMed ID: 3991542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Red blood cell aluminum in patients with renal failure and effect of desferrioxamine infusion.
    Umeda M; Tsurusaki K; Kamikawa S; Izumi N; Yasumoto R; Kishimoto T; Maekawa M
    Blood Purif; 1990; 8(5):295-300. PubMed ID: 2091689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Disseminated mucormycosis in a hemodialyzed female patient treated with deferoxamine].
    Ponz E; Campistol JM; Ribalta T; Montoliú J; Ramírez J; Almirall J; Revert L
    Rev Clin Esp; 1991 Feb; 188(2):85-7. PubMed ID: 2041907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aluminum intoxication in a child: treatment with intraperitoneal desferrioxamine.
    Warady BA; Ford DM; Gaston CE; Sedman AB; Huffer WE; Lum GM
    Pediatrics; 1986 Oct; 78(4):651-5. PubMed ID: 3763276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Causes of hyperaluminemia in patients maintained on hemodialysis].
    Balezina OA; Ermolenko VM; Bel'skii NK; Nebol'sina LA; Segel'man VS
    Ter Arkh; 1982; 54(7):85-6. PubMed ID: 7135231
    [No Abstract]   [Full Text] [Related]  

  • 34. Low serum aluminum values in dialysis patients with increased bone aluminum levels.
    van Landeghem GF; D'Haese PC; Lamberts LV; Djukanovic L; Pejanovic S; Goodman WG; De Broe ME
    Clin Nephrol; 1998 Aug; 50(2):69-76. PubMed ID: 9725776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Verification of desferrioxamine ototoxicity by high-frequency audiometry in patients undergoing dialysis].
    Martín C; Lens XM; Prieto A; Alonso R; Correa B; Arcocha V; Soto A
    An Otorrinolaringol Ibero Am; 1994; 21(2):193-8. PubMed ID: 8209972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of desferrioxamine in dialysis-associated mucormycosis: report of three cases and review of the literature.
    Boelaert JR; van Roost GF; Vergauwe PL; Verbanck JJ; de Vroey C; Segaert MF
    Clin Nephrol; 1988 May; 29(5):261-6. PubMed ID: 3293856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of aluminum-induced osteopathy with desferrioxamine in dialysis-dependent renal failure].
    Lechleitner P; Gmeiner R; Beck G; König P
    Wien Med Wochenschr; 1987 Aug; 137(14-15):355-60. PubMed ID: 3673100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Successful treatment of progressive dialysis encephalopathy. Case report].
    Weiland P; Köhler M; Glatzel E
    Z Urol Nephrol; 1985 Jul; 78(7):387-93. PubMed ID: 4050157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Erythropoietin and improvement in the erythropoiesis of chronic hemodialysis patients treated with desferrioxamine.
    de la Serna FJ; Gilsanz F; Praga M; Estenoz J
    Clin Nephrol; 1991 Sep; 36(3):157-8. PubMed ID: 1934678
    [No Abstract]   [Full Text] [Related]  

  • 40. [Pigmentary changes of the retina in dialysis patients treated with deferoxamine].
    Mathys B; Baeck A; Verougstraete C; Verstappen A; D'Haene M; Zanen A
    Bull Soc Belge Ophtalmol; 1988; 229():49-60. PubMed ID: 3273254
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.